ランキングに戻る

ICU Medical, Inc. (ICUI)

NEUTRAL
HealthcareMedical Instruments & SuppliesUnited States

ファンダメンタル

49

株価

$183.10

時価総額

$4.55B

パート1 · 企業の価値

概要

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

貸借対照表と流動性

売上高

$2.16B

直近12か月(2026/6/30まで)

純利益

$30M

直近12か月(2026/6/30まで)

フリーキャッシュフロー

$92M

自己資本合計

$2.12B

負債合計

$1.93B

流動比率

2.43

利払い倍率

0.87

負債/EBITDA

5.28

一株当たり利益(EPS)

売上高と純利益

フリーキャッシュフロー

収益内訳

財務推移表

利益率の推移

負債の推移

負債の重さ

成長率グリッド

成長率 — 売上高

適正価値の推定

General case割高

適正価値

$102.68

現在株価

$183.10

安全マージン

-78.3%

適正価値レンジ

$66.74 - $138.62

推定方法

Analyst price target:$193.38
Discounted cash flow (DCF):$117.21
Earnings multiple (P/E):$22.75
Graham growth formula:$8.90
Earnings power value (EPV):$29.87
Justified P/B:Not enough data to compute it
Dividend discount (Gordon):Not enough data to compute it
P/FFO, funds from operations:Not enough data to compute it
Mid-cycle earnings:$234.96
Revenue multiple:Not enough data to compute it
アナリスト・コンセンサス:強い買い (12B / 1H / 0S)
直近の決算サプライズ:+21.43%

バリュエーション指標

P/E レシオ

153.40

ROE

0.0%

P/B レシオ

2.12

P/FCF

29.87

粗利益率

39.1%

ROIC

1.6%

収益性レーダー

Value Creation (Economic Moat)

ROIC

1.6%

WACC

8.5%

ROIC − WACC

-6.8 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

ファンダメンタル分析基準

合格(14)

  • Gross Margin 39.1%
  • P/FCF 29.87
  • P/B Ratio 2.12
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • Current Ratio
  • Debt/EBITDA
  • Revenue Growth 5Y 11.9%
  • Analyst Consensus 92% Buy
  • Earnings Surprise avg 20.3%
  • Earnings Quality (OCF/NI) 7.86
  • Share Dilution 0.1%
  • Net Margin Trend 1.4% vs -1.6%
  • Piotroski F-Score 7/9

不合格(12)

  • EPS shows upward trend
  • EPS CAGR -19.56%
  • Price CAGR 2.18%
  • ROIC 1.6%
  • Operating Margin 3.3%
  • CapEx intensity
  • Interest Coverage
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • ROE 2.2%

データなし(2)

  • Dividend Payout NaN%
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-スコア

7/9

財務健全性が高い

score
criteria

利益の質

7.86

高品質:利益はキャッシュに裏付けられている

株式希薄化

0.1%

株式数は安定している

ガバナンス

経営陣

氏名役職年齢
Mr. Vivek JainCEO & Chairman of the Board53
Mr. Daniel WoolsonPresident48
Mr. Brian Michael BonnellCFO & Treasurer51
Mr. Christian B. VoigtlanderChief Operating Officer57
Ms. Virginia Ruth SanzoneCorporate VP, General Counsel, Secretary & Compliance Officer50
Ben SousaChief Information Officer-
Olivia BarrallVice President of Human Resources-

監査リスク

5

取締役会リスク

4

報酬リスク

4

株主権利リスク

5

パート2 · 株価と買い時

この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容:テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。

Latest News

Recent headlines for ICUI, sourced from Markets Gazette.

No recent news for ICUI.